CardioGenics has received the Canadian Intellectual Property Office grant for the patent application of 'core technology' of its ultra-sensitive point-of-care immuno-analyzer, the QL Care Analyzer.
Patents covering the ‘core technology’ have now been issued in Canada, the European Union and Japan.
A patent application for the ‘core technology’ is currently pending in the US before the US Patent and Trademark Office (USPTO).
CardioGenics CEO Yahia Gawad said they are pleased that the patent offices of Canada, the European Union and Japan have acknowledged the nature of the ‘core technology’ upon which QL Care Analyzer is based.
"The granting of these patents in these major commercial markets further enhances the value of CardioGenics’ intellectual property portfolio and we now look forward to a similar disposition of our patent application for the ‘core technology’ from the USPTO," Gawad said.